Flash FinanceUS
Market open S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Turn Therapeutics Inc. (TTRX)

Turn Therapeutics files updated investor presentation; cash runway into Q3 2027

Neutral Impact 2 of 5 other

Turn Therapeutics furnished an updated November 2026 investor presentation under Regulation FD as Exhibit 99.1. The presentation restates a Q1 2027 topline readout for its GX-03 Phase 2 trial in moderate to severe atopic dermatitis and reports $10.4 million in cash as of September 30, 2026, with runway into Q3 2027 and additional capital available under existing facilities.

Key points

  • Cash balance of $10.4 million as of September 30, 2026; cash runway into Q3 2027
  • Phase 2 topline results for GX-03 in atopic dermatitis expected in Q1 2027
  • About 30.5 million common shares outstanding as of September 30, 2026
  • About $33 million raised since inception (2015) and about $24 million cash burned since inception

The filing

CompanyTurn Therapeutics Inc. (TTRX)
Form8-K, current report
Filed with the SECNov 10, 2026, 8:05 AM ET
Accession number0001213900-26-117781

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 10, 2026, 8:16 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.